147 results on '"Chen, Zhe-Sheng"'
Search Results
2. Hepatocellular carcinoma and lipid metabolism: Novel targets and therapeutic strategies
- Author
-
Cao, Lu-Qi, Xie, Yuhao, Fleishman, Joshua S., Liu, Xuan, and Chen, Zhe-Sheng
- Published
- 2024
- Full Text
- View/download PDF
3. Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer
- Author
-
Shukla, Siddhant, Patel, Harsh, Chen, Shuzhen, Sun, Rainie, Wei, Liuya, and Chen, Zhe-Sheng
- Published
- 2024
- Full Text
- View/download PDF
4. A novel nitric oxide-driven nanomotor for synergistic treatment of ischaemic stroke: Enhanced deep brain penetration and therapeutic efficacy
- Author
-
Xiao, Zhicheng, Li, Yi, Chen, Ting, Xie, Chenchen, Liao, Jun, Lin, Pu, Chen, Zhe-Sheng, Qiu, Yan, Cai, Jian, Zhang, Chuan, and Wang, Tingfang
- Published
- 2024
- Full Text
- View/download PDF
5. Stepwise targeted strategies for improving neurological function by inhibiting oxidative stress levels and inflammation following ischemic stroke
- Author
-
Li, Yi, Liao, Jun, Xiong, Liyan, Xiao, Zhicheng, Ye, Fei, Wang, Yun, Chen, Ting, Huang, Linzhang, Chen, Min, Chen, Zhe-Sheng, Wang, Tingfang, Zhang, Chuan, and Lu, Ying
- Published
- 2024
- Full Text
- View/download PDF
6. AR/RKIP pathway mediates the inhibitory effects of icariin on renal fibrosis and endothelial-to-mesenchymal transition in type 2 diabetic nephropathy
- Author
-
Yao, Wenhui, Tao, Rongpin, Xu, Yue, Chen, Zhe-Sheng, Ding, Xuansheng, and Wan, Lisheng
- Published
- 2024
- Full Text
- View/download PDF
7. SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest
- Author
-
Wang, Chong, Wang, Tao, Li, Kang-Jing, Hu, Ling-Hong, Li, Yue, Yu, Yu-Zhong, Xie, Tao, Zhu, Sha, Fu, Du-Jiang, Wang, Yang, Zeng, Xian-Zi, Liu, Feng-Ping, Chen, Hong, Chen, Zhe-Sheng, Feng, Ning-Han, Liu, Jinghua, Jiang, Yong, and Zhao, Shan-Chao
- Published
- 2023
- Full Text
- View/download PDF
8. A multi-functional nano-system combining PI3K-110α/β inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency
- Author
-
Lin, Ruikun, Zhang, Lei, Ye, Biwei, Wang, Yanan, Li, Yi-Dong, Jason, Hsu, Liu, Wenzhen, Hu, Ping, Chen, Jincan, Chen, Zhe-Sheng, and Chen, Zhuo
- Published
- 2023
- Full Text
- View/download PDF
9. Recent advances in biomimetic nanodelivery systems: New brain-targeting strategies
- Author
-
Liao, Jun, Fan, Li, Li, Yi, Xu, Qing-Qiang, Xiong, Li-Yan, Zhang, Shan-Shan, Liu, Ji-Hao, Xiao, Zhi-Cheng, Zhang, Chuan, Yang, Jian, Chen, Zhe-Sheng, Xiao, Kai, Wang, Ting-Fang, and Lu, Ying
- Published
- 2023
- Full Text
- View/download PDF
10. Formulation and characterization of oleic acid magnetic PEG PLGA nanoparticles for targeting glioblastoma multiforme
- Author
-
Jani, Khushboo, Kaushal, Neeraj, Sadoqi, Mostafa, Long, Gen, Chen, Zhe-Sheng, and Squillante, Emilio
- Published
- 2021
- Full Text
- View/download PDF
11. Bypassing P-glycoprotein mediated efflux of afatinib by cyclodextrin complexation – Evaluation of intestinal absorption and anti-cancer activity
- Author
-
Parvathaneni, Vineela, Elbatanony, Rasha S., Shukla, Snehal K., Kulkarni, Nishant S., Kanabar, Dipti D., Chauhan, Gautam, Ayehunie, Seyoum, Chen, Zhe-Sheng, Muth, Aaron, and Gupta, Vivek
- Published
- 2021
- Full Text
- View/download PDF
12. Research progress of traditional Chinese medicine influencing macrophage polarization
- Author
-
GAO, Shuang, CHEN, Zhe-Sheng, CHEN, Xuanyu, and LI, Jing
- Published
- 2021
- Full Text
- View/download PDF
13. A multi-functionalized nanocomposite constructed by gold nanorod core with triple-layer coating to combat multidrug resistant colorectal cancer
- Author
-
Jiang, Yajun, Guo, Zhaoyang, Fang, Jing, Wang, Beibei, Lin, Zhiqiang, Chen, Zhe-Sheng, Chen, Yan, Zhang, Ning, Yang, Xiaoying, and Gao, Wei
- Published
- 2020
- Full Text
- View/download PDF
14. Patterned synthesis of ZnO nanorod arrays for nanoplasmonic waveguide applications
- Author
-
Lamson, Thomas L., Khan, Sahar, Wang, Zhifei, Zhang, Yun-Kai, Yu, Yong, Chen, Zhe-Sheng, and Xu, Huizhong
- Published
- 2018
- Full Text
- View/download PDF
15. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study
- Author
-
Wang, Yi-Jun, Zhang, Yun-Kai, Zhang, Guan-Nan, Al Rihani, Sweilem B., Wei, Meng-Ning, Gupta, Pranav, Zhang, Xiao-Yu, Shukla, Suneet, Ambudkar, Suresh V., Kaddoumi, Amal, Shi, Zhi, and Chen, Zhe-Sheng
- Published
- 2017
- Full Text
- View/download PDF
16. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia
- Author
-
Gupta, Pranav, Kathawala, Rishil J., Wei, Liuya, Wang, Fang, Wang, XiaoKun, Druker, Brian J., Fu, Li-Wu, and Chen, Zhe-Sheng
- Published
- 2016
- Full Text
- View/download PDF
17. Cytokines in cancer drug resistance: Cues to new therapeutic strategies
- Author
-
Jones, Valerie Sloane, Huang, Ren-Yu, Chen, Li-Pai, Chen, Zhe-Sheng, Fu, Liwu, and Huang, Ruo-Pan
- Published
- 2016
- Full Text
- View/download PDF
18. Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers.
- Author
-
Zhang, Lei, Ye, Biwei, Chen, Zhuo, and Chen, Zhe-Sheng
- Subjects
MULTIDRUG resistance ,ALTERNATIVE RNA splicing ,CANCER chemotherapy ,ANTINEOPLASTIC agents ,NON-coding RNA - Abstract
Chemotherapy is one of the important methods to treat cancer, and the emergence of multidrug resistance (MDR) is one major cause for the failure of cancer chemotherapy. Almost all anti-tumor drugs develop drug resistance over a period of time of application in cancer patients, reducing their effects on killing cancer cells. Chemoresistance can lead to a rapid recurrence of cancers and ultimately patient death. MDR may be induced by multiple mechanisms, which are associated with a complex process of multiple genes, factors, pathways, and multiple steps, and today the MDR-associated mechanisms are largely unknown. In this paper, from the aspects of protein–protein interactions, alternative splicing (AS) in pre-mRNA, non-coding RNA (ncRNA) mediation, genome mutations, variance in cell functions, and influence from the tumor microenvironment, we summarize the molecular mechanisms associated with MDR in cancers. In the end, prospects for the exploration of antitumor drugs that can reverse MDR are briefly discussed from the angle of drug systems with improved targeting properties, biocompatibility, availability, and other advantages. Multiple mechanisms associated with MDR in cancers. On the levels of regulatory by anti-tumor drugs, signaling pathways, gene mutations and miRNAs, etc., MDR in cancers could be induced. Clarification of these regulations will unveil potential targets for cancer treatment by combined chemotherapy. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2
- Author
-
Zhao, Xiao-qin, Dai, Chun-ling, Ohnuma, Shinobu, Liang, Yong-ju, Deng, Wen, Chen, Jun-Jiang, Zeng, Mu-Sheng, Ambudkar, Suresh V., Chen, Zhe-Sheng, and Fu, Li-Wu
- Published
- 2013
- Full Text
- View/download PDF
20. Targeting anoikis resistance as a strategy for cancer therapy.
- Author
-
Wang, Yumin, Cheng, Sihang, Fleishman, Joshua S., Chen, Jichao, Tang, Hailin, Chen, Zhe-Sheng, Chen, Wenkuan, and Ding, Mingchao
- Abstract
Anoikis, known as matrix detachment-induced apoptosis or detachment-induced cell death, is crucial for tissue development and homeostasis. Cancer cells develop means to evade anoikis, e.g. anoikis resistance, thereby allowing for cells to survive under anchorage-independent conditions. Uncovering the mechanisms of anoikis resistance will provide details about cancer metastasis, and potential strategies against cancer cell dissemination and metastasis. Here, we summarize the principal elements and core molecular mechanisms of anoikis and anoikis resistance. We discuss the latest progress of how anoikis and anoikis resistance are regulated in cancers. Furthermore, we summarize emerging data on selective compounds and nanomedicines, explaining how inhibiting anoikis resistance can serve as a meaningful treatment modality against cancers. Finally, we discuss the key limitations of this therapeutic paradigm and possible strategies to overcome them. In this review, we suggest that pharmacological modulation of anoikis and anoikis resistance by bioactive compounds could surmount anoikis resistance, highlighting a promising therapeutic regimen that could be used to overcome anoikis resistance in cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Preclinical studies of the triazolo[1,5-a]pyrimidine derivative WS-716 as a highly potent, specific and orally active P-glycoprotein (P-gp) inhibitor.
- Author
-
Wang, Sai-Qi, Teng, Qiu-Xu, Wang, Shuai, Lei, Zi-Ning, Hu, Hui-Hui, Lv, Hui-Fang, Chen, Bei-Bei, Wang, Jian-Zheng, Shi, Xiao-Jing, Xu, Wei-Feng, Liu, Hong-Min, Chen, Xiao-Bing, Chen, Zhe-Sheng, and Yu, Bin
- Subjects
PACLITAXEL ,P-glycoprotein ,PYRIMIDINE derivatives ,MULTIDRUG resistance ,CELL cycle ,CANCER treatment - Abstract
Multidrug resistance (MDR) is the main cause of clinical treatment failure and poor prognosis in cancer. Targeting P-glycoprotein (P-gp) has been regarded as an effective strategy to overcome MDR. In this work, we reported our preclinical studies of the triazolo[1,5- a ]pyrimidine-based compound WS-716 as a highly potent, specific, and orally active P-gp inhibitor. Through direct binding to P-gp, WS-716 inhibited efflux function of P-gp and specifically reversed P-gp-mediated MDR to paclitaxel (PTX) in multiple resistant cell lines, without changing its expression or subcellular localization. WS-716 and PTX synergistically inhibited formation of colony and 3D spheroid, induced apoptosis and cell cycle arrest at G2/M phase in resistant SW620/Ad300 cells. In addition, WS-716 displayed minimal effect on the drug-metabolizing enzyme cytochrome P4503A4 (CYP3A4). Importantly, WS-716 increased sensitivity of both pre-clinically and clinically derived MDR tumors to PTX in vivo with the T/C value of 29.7% in patient-derived xenograft (PDX) models. Relative to PTX treatment alone, combination of WS-716 and PTX caused no obvious adverse reactions. Taken together, our preclinical studies revealed therapeutic promise of WS-716 against MDR cancer, the promising data warrant its further development for cancer therapy. Preclinical studies reveal that WS-716 is a highly potent, specific and orally active P-glycoprotein inhibitor and increases sensitivity of both pre-clinically and clinically derived MDR tumors to PTX in vivo. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Detailed resume of RNA m6A demethylases.
- Author
-
Shen, Dandan, Wang, Bo, Gao, Ya, Zhao, Lijuan, Bi, Yaping, Zhang, Jinge, Wang, Ning, Kang, Huiqin, Pang, Jingru, Liu, Ying, Pang, Luping, Chen, Zhe-Sheng, Zheng, Yi-Chao, and Liu, Hong-Min
- Subjects
RNA ,ADIPOSE tissues ,MEDICAL screening ,MESSENGER RNA ,DEMETHYLATION - Abstract
N 6-Methyladenosine (m
6 A) is the most abundant internal modification in eukaryotic mRNA, playing critical role in various bioprocesses. Like other epigenetic modifications, m6 A modification can be catalyzed by the methyltransferase complex and erased dynamically to maintain cells homeostasis. Up to now, only two m6 A demethylases have been reported, fat mass and obesity-associated protein (FTO) and alkylation protein AlkB homolog 5 (ALKBH5), involving in a wide range of mRNA biological progress, including mRNA shearing, export, metabolism and stability. Furthermore, they participate in many significantly biological signaling pathway, and contribute to the progress and development of cancer along with other diseases. In this review, we focus on the studies about structure, inhibitors development and biological function of FTO and ALKBH5. This review systematically describes the chemical and biological functions of RNA demethylases FTO and ALKBH5, from their crystal structure to inhibitors development and screening, demethylation mechanism and substrates to biological functions and roles in diseases. [Display omitted] [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
23. MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study.
- Author
-
Wu, Zhuo-Xun, Teng, Qiu-Xu, Yang, Yuqi, Acharekar, Nikita, Wang, Jing-Quan, He, Min, Yoganathan, Sabesan, Lin, Jun, Wang, Jian, and Chen, Zhe-Sheng
- Subjects
MULTIDRUG resistance ,GENETIC overexpression ,IN vivo studies ,GENE knockout ,IN vitro studies - Abstract
Overexpression of ABCG2 transporter in cancer cells has been linked to the development of multidrug resistance (MDR), an obstacle to cancer therapy. Our recent study uncovered that the MET inhibitor, tepotinib, is a potent reversal agent for ABCB1-mediated MDR. In the present study, we reported for the first time that the MET inhibitor tepotinib can also reverse ABCG2-mediated MDR in vitro and in vivo by directly binding to the drug-binding site of ABCG2 and reversibly inhibiting ABCG2 drug efflux activity, therefore enhancing the cytotoxicity of substrate drugs in drug-resistant cancer cells. Furthermore, the ABCB1/ABCG2 double-transfected cell model and ABCG2 gene knockout cell model demonstrated that tepotinib specifically inhibits the two MDR transporters. In mice bearing drug-resistant tumors, tepotinib increased the intratumoral accumulation of ABCG2 substrate drug topotecan and enhanced its antitumor effect. Therefore, our study provides a new potential of repositioning tepotinib as an ABCG2 inhibitor and combining tepotinib with substrate drugs to antagonize ABCG2-mediated MDR. Tepotinib antagonizes multidrug resistance (MDR) by inhibiting the efflux function of ABCG2 transporter, thereby increasing the intracellular substrate drug concentration, and enhancing its cytotoxic effect in MDR cancer cells. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C.
- Author
-
Lei, Zi-Ning, Albadari, Najah, Teng, Qiu-Xu, Rahman, Hadiar, Wang, Jing-Quan, Wu, Zhongzhi, Ma, Dejian, Ambudkar, Suresh V., Wurpel, John N.D., Pan, Yihang, Li, Wei, and Chen, Zhe-Sheng
- Abstract
To investigate the collateral sensitivity (CS) of ABCB1-positive multidrug resistant (MDR) colorectal cancer cells to the survivin inhibitor MX106–4C and the mechanism. Biochemical assays (MTT, ATPase, drug accumulation/efflux, Western blot, RT-qPCR, immunofluorescence, flow cytometry) and bioinformatic analyses (mRNA-sequencing, reversed-phase protein array) were performed to investigate the hypersensitivity of ABCB1 overexpressing colorectal cancer cells to MX106–4C and the mechanisms. Synergism assay, long-term selection, and 3D tumor spheroid test were used to evaluate the anti-cancer efficacy of MX106–4C. MX106–4C selectively killed ABCB1-positive colorectal cancer cells, which could be reversed by an ABCB1 inhibitor, knockout of ABCB1, or loss-of-function ABCB1 mutation, indicating an ABCB1 expression and function-dependent mechanism. MX106–4C's selective toxicity was associated with cell cycle arrest and apoptosis through ABCB1-dependent survivin inhibition and activation on caspases-3/7 as well as modulation on p21-CDK4/6-pRb pathway. MX106–4C had good selectivity against ABCB1-positive colorectal cancer cells and retained this in multicellular tumor spheroids. In addition, MX106–4C could exert a synergistic anti-cancer effect with doxorubicin or re-sensitize ABCB1-positive cancer cells to doxorubicin by reducing ABCB1 expression in the cell population via long-term exposure. MX106–4C selectively kills ABCB1-positive MDR colorectal cancer cells via a novel ABCB1-dependent survivin inhibition mechanism, providing a clue for designing CS compound as an alternative strategy to overcome ABCB1-mediated colorectal cancer MDR. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor.
- Author
-
Teng, Qiu-Xu, Lei, Zi-Ning, Wang, Jing-Quan, Yang, Yuqi, Wu, Zhuo-Xun, Acharekar, Nikita Dilip, Zhang, Wei, Yoganathan, Sabesan, Pan, Yihang, Wurpel, John, Chen, Zhe-Sheng, and Fang, Shuo
- Abstract
The overexpression of ABC transporters on cancer cell membranes is one of the most common causes of multidrug resistance (MDR). This study investigates the impact of ABCC1 and ABCG2 on the resistance to talazoparib (BMN-673), a potent poly (ADP-ribose) polymerase (PARP) inhibitor, in ovarian cancer treatment. The cell viability test was used to indicate the effect of talazoparib in different cell lines. Computational molecular docking analysis was conducted to simulate the interaction between talazoparib and ABCC1 or ABCG2. The mechanism of talazoparib resistance was investigated by constructing talazoparib-resistant subline A2780/T4 from A2780 through drug selection with gradually increasing talazoparib concentration. Talazoparib cytotoxicity decreased in drug-selected or gene-transfected cell lines overexpressing ABCC1 or ABCG2 but can be restored by ABCC1 or ABCG2 inhibitors. Talazoparib competitively inhibited substrate drug efflux activity of ABCC1 or ABCG2. Upregulated ABCC1 and ABCG2 protein expression on the plasma membrane of A2780/T4 cells enhances resistance to other substrate drugs, which could be overcome by the knockout of either gene. In vivo experiments confirmed the retention of drug-resistant characteristics in tumor xenograft mouse models. The therapeutic efficacy of talazoparib in cancer may be compromised by its susceptibility to MDR, which is attributed to its interactions with the ABCC1 or ABCG2 transporters. The overexpression of these transporters can potentially diminish the therapeutic impact of talazoparib in cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells.
- Author
-
Wang, Jinxiang, Zeng, Leli, Wu, Nisha, Liang, Yanling, Jin, Jie, Fan, Mingming, Lai, Xiaoju, Chen, Zhe-Sheng, Pan, Yihang, Zeng, Fangyin, and Deng, Fan
- Abstract
Phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in the first step of the serine synthesis pathway (SSP), is overexpressed in multiple types of cancers. The androgen receptor inhibitor enzalutamide (Enza) is the primary therapeutic drug for patients with castration-resistant prostate cancer (CRPC). However, most patients eventually develop resistance to Enza. The association of SSP with Enza resistance remains unclear. In this study, we found that high expression of PHGDH was associated with Enza resistance in CRPC cells. Moreover, increased expression of PHGDH led to ferroptosis resistance by maintaining redox homeostasis in Enza-resistant CRPC cells. Knockdown of PHGDH caused significant GSH reduction, induced lipid peroxides (LipROS) increase and significant cell death, resulting in inhibiting growth of Enza-resistant CRPC cells and sensitizing Enza-resistant CRPC cells to enzalutamide treatment both in vitro and in vivo. We also found that overexpression of PHGDH promoted cell growth and Enza resistance in CRPC cells. Furthermore, pharmacological inhibition of PHGDH by NCT-503 effectively inhibited cell growth, induced ferroptosis, and overcame enzalutamide resistance in Enza-resistant CRPC cells both in vitro and in vivo. Mechanically, NCT-503 triggered ferroptosis by decreasing GSH/GSSG levels and increasing LipROS production as well as suppressing SLC7A11 expression through activation of the p53 signaling pathway. Moreover, stimulating ferroptosis by ferroptosis inducers (FINs) or NCT-503 synergistically sensitized Enza-resistant CRPC cells to enzalutamide. The synergistic effects of NCT-503 and enzalutamide were verified in a xenograft nude mouse model. NCT-503 in combination with enzalutamide effectively restricted the growth of Enza-resistant CRPC xenografts in vivo. Overall, our study highlights the essential roles of increased PHGDH in mediating enzalutamide resistance in CRPC. Therefore, the combination of ferroptosis inducer and targeted inhibition of PHGDH could be a potential therapeutic strategy for overcoming enzalutamide resistance in CRPC. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Enhanced transport of anticancer agents and leukotriene C 4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2)
- Author
-
Kawabe, Takeshi, Chen, Zhe-Sheng, Wada, Morimasa, Uchiumi, Takeshi, Ono, Mayumi, Akiyama, Shin-ichi, and Kuwano, Michihiko
- Published
- 1999
- Full Text
- View/download PDF
28. The epigallocatechin gallate derivative Y6 reverses drug resistance mediated by the ABCB1 transporter both in vitro and in vivo.
- Author
-
Wen, Yan, Zhao, Ruiqiang, Gupta, Pranav, Fan, Yingfang, Zhang, Yunkai, Huang, Zhenguang, Li, Xiaohui, Su, Yuangang, Liao, Lijuan, Xie, Yu-An, Yang, Donghua, Chen, Zhe-Sheng, and Liang, Gang
- Subjects
ATP-binding cassette transporters ,EPIGALLOCATECHIN gallate ,DRUG resistance - Abstract
Abstract Previously, we reported that Y 6 , a new epigallocatechin gallate derivative, is efficacious in reversing doxorubicin (DOX)--mediated resistance in hepatocellular carcinoma BEL-7404/DOX cells. In this study, we evaluated the efficacy of Y 6 in reversing drug resistance both in vitro and in vivo by determining its effect on the adenosine triphosphate-binding cassette protein B1 transporter (ABCB1 or P-glycoprotein, P-gp). Our results showed that Y 6 significantly sensitized cells overexpressing the ABCB1 transporter to anticancer drugs that are ABCB1 substrates. Y 6 significantly stimulated the adenosine triphosphatase activity of ABCB1. Furthermore, Y 6 exhibited a higher docking score as compared with epigallocatechin gallate inside the transmembrane domain of ABCB1. In addition, in the nude mouse tumor xenograft model, Y 6 (110 mg/kg, intragastric administration), in combination with doxorubicin (2 mg/kg, intraperitoneal injection), significantly inhibited the growth of BEL-7404/DOX cell xenograft tumors, compared to equivalent epigallocatechin gallate. In conclusion, Y 6 significantly reversed ABCB1-mediated multidrug resistance and its mechanisms of action may result from its competitive inhibition of the ABCB1 drug efflux function. Graphical abstract Y 6 , an epigallocatechin gallate derivative, reverses ABCB1-mediated multidrug resistance in vitro and in vivo , and the reversal effect of Y 6 is significantly greater than epigallocatechin gallate. fx1 Highlights • Y 6 , an epigallocatechin gallate derivative, reverses ABCB1-mediated multidrug resistance in vitro and in vivo , and the reversal effect of Y 6 is significantly greater than epigallocatechin gallate. • Y 6 stimulates ABCB1 ATPase activity. • Y 6 has a significantly higher docking score than epigallocatechin gallate, Y 6 combined with doxorubicin suppressed the growth of resistant hepatocellular carcinoma tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
29. Modulating ROS to overcome multidrug resistance in cancer.
- Author
-
Cui, Qingbin, Wang, Jing-Quan, Assaraf, Yehuda G., Ren, Liang, Gupta, Pranav, Wei, Liuya, Ashby, Charles R., Yang, Dong-Hua, and Chen, Zhe-Sheng
- Abstract
Abstract The successful treatment of cancer has significantly improved as a result of targeted therapy and immunotherapy. However, during chemotherapy, cancer cells evolve and can acquire "multidrug resistance" (MDR), which significantly limits the efficacy of cancer treatment and impacts patient survival and quality of life. Among the approaches to reverse MDR, modulating reactive oxidative species (ROS) may represent a strategy to kill MDR cancer cells that are mechanistically diverse. ROS in cancer cells play a central role in regulating and inducing apoptosis, thereby modulating cancer cells proliferation, survival and drug resistance. The levels of ROS and the activity of scavenging/anti-oxidant enzymes in drug resistant cancer cells are typically increased compared to non-MDR cancer and normal cells. Consequently, MDR cancer cells may be more susceptible to alterations in ROS levels. Numerous studies suggest that compounds modulating cellular ROS levels can enhance MDR cancer cell death and sensitize MDR cancer cells to certain chemotherapeutic drugs. In the current review, we discuss the critical and targetable redox-regulating enzymes, including mitochondrial electron transport chain (ETC) complexes, NADPH oxidases (NOXs), enzymes related to glutathione metabolism, glutamate/cystine antiporter xCT, thioredoxin reductases (TrxRs), nuclear factor erythroid 2-related factor 2 (Nrf2), and their roles in regulating cellular ROS levels, drug resistance as well as their clinical significance. We also discuss and summarize the findings in the past decade regarding the efficacy of ROS modulators for the treatment of MDR cancer alone or as sensitizing compounds. Compounds that are efficacious in modulating ROS generation represent a prominent class of drug candidates that warrants evaluation in clinical trials for patients harboring MDR cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2.
- Author
-
Wen, Qing, Huang, Maohua, Xie, Jingwen, Liu, Runyu, Miao, Qun, Huang, Jinjun, Zhang, Junqiu, lyu, Wenyu, Qi, Ming, Wu, Chunyi, Qi, Qi, Zhang, Zhijing, Deng, Rong, Wang, Chenran, Chen, Zhe-Sheng, Zhang, Dongmei, Ye, Wencai, and Chen, Minfeng
- Abstract
Vessel co-option is responsible for tumor resistance to antiangiogenic therapies (AATs) in patients with colorectal cancer liver metastasis (CRCLM). However, the mechanisms underlying vessel co-option remain largely unknown. Herein, we investigated the roles of a novel lncRNA SYTL5-OT4 and Alanine-Serine-Cysteine Transporter 2 (ASCT2) in vessel co-option-mediated AAT resistance. SYTL5-OT4 was identified by RNA-sequencing and verified by RT-qPCR and RNA fluorescence in situ hybridization assays. The effects of SYTL5-OT4 and ASCT2 on tumor cells were investigated by gain- and loss-of-function experiments, and those of SYTL5-OT4 on ASCT2 expression were analyzed by RNA immunoprecipitation and co-immunoprecipitation assays. The roles of SYTL5-OT4 and ASCT2 in vessel co-option were detected by histological, immunohistochemical, and immunofluorescence analyses. The expression of SYTL5-OT4 and ASCT2 was higher in patients with AAT-resistant CRCLM. SYTL5-OT4 enhanced the expression of ASCT2 by inhibiting its autophagic degradation. SYTL5-OT4 and ASCT2 promoted vessel co-option by increasing the proliferation and epithelial-mesenchymal transition of tumor cells. Combination therapy of ASCT2 inhibitor and antiangiogenic agents overcame vessel co-option-mediated AAT resistance in CRCLM. This study highlights the crucial roles of lncRNA and glutamine metabolism in vessel co-option and provides a potential therapeutic strategy for patients with AAT-resistant CRCLM. • SYTL5-OT4 and ASCT2 in tumor cells involve in vessel co-option-mediated AAT resistance. • SYTL5-OT4 binds to ASCT2 to inhibit its autophagy-lysosome degradation. • Targeting SYTL5-OT4 or ASCT2 circumvents the vessel co-option-mediated AAT resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Establishment and characterization of arsenic trioxide resistant KB/ATO cells.
- Author
-
Zhang, Yun-Kai, Dai, Chunling, Yuan, Chun-gang, Wu, Hsiang-Chun, Xiao, Zhijie, Lei, Zi-Ning, Yang, Dong-Hua, Le, X. Chris, Fu, Liwu, and Chen, Zhe-Sheng
- Subjects
ARSENIC trioxide ,TREATMENT of acute promyelocytic leukemia ,ANTINEOPLASTIC agents ,MULTIDRUG resistance ,TREATMENT effectiveness ,P-glycoprotein ,GENE expression - Abstract
Arsenic trioxide (ATO) is used as a chemotherapeutic agent for the treatment of acute promyelocytic leukemia. However, increasing drug resistance is reducing its efficacy. Therefore, a better understanding of ATO resistance mechanism is required. In this study, we established an ATO-resistant human epidermoid carcinoma cell line, KB/ATO, from its parental KB-3-1 cells. In addition to ATO, KB/ATO cells also exhibited cross-resistance to other anticancer drugs such as cisplatin, antimony potassium tartrate, and 6-mercaptopurine. The arsenic accumulation in KB/ATO cells was significantly lower than that in KB-3-1 cells. Further analysis indicated that neither application of P-glycoprotein inhibitor, breast cancer resistant protein (BCRP) inhibitor, or multidrug resistance protein 1 (MRP1) inhibitor could eliminate ATO resistance. We found that the expression level of ABCB6 was increased in KB/ATO cells. In conclusion, ABCB6 could be an important factor for ATO resistance in KB/ATO cells. The ABCB6 level may serve as a predictive biomarker for the effectiveness of ATO therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Antimicrobial peptides for combating drug-resistant bacterial infections.
- Author
-
Xuan, Jiaqi, Feng, Weiguo, Wang, Jiaye, Wang, Ruichen, Zhang, Bowen, Bo, Letao, Chen, Zhe-Sheng, Yang, Hui, and Sun, Leming
- Abstract
The problem of drug resistance due to long-term use of antibiotics has been a concern for years. As this problem grows worse, infections caused by multiple bacteria are expanding rapidly and are extremely detrimental to human health. Antimicrobial peptides (AMPs) are a good alternative to current antimicrobials with potent antimicrobial activity and unique antimicrobial mechanisms, which have advantages over traditional antibiotics in fighting against drug-resistant bacterial infections. Currently, researchers have conducted clinical investigations on AMPs for drug-resistant bacterial infections while integrating new technologies in the development of AMPs, such as changing amino acid structure of AMPs and using different delivery methods for AMPs. This article introduces the basic properties of AMPs, deliberates the mechanism of drug resistance in bacteria and the therapeutic mechanism of AMPs. The current disadvantages and advances of AMPs in combating drug-resistant bacterial infections are also discussed. This article provides important insights into the research and clinical application of new AMPs for drug-resistant bacterial infections. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Silver-dendrimer nanocomposite as emerging therapeutics in anti-bacteria and beyond.
- Author
-
Fu, Xiaoling, Rehman, Urushi, Wei, Liuya, Chen, Zhe-Sheng, Abourehab, Mohammed A.S., Kesharwani, Prashant, and Cheng, Zhi-Hong
- Abstract
To develop next-generation nanomedicine, theranostic nanotherapeutic strategies are increasingly being emphasized. In recent years, it is observed that the effective lifetime of anti-bacterial and anti-cancer agent is diminishing, which undermines the economic incentives necessary for clinical development and therapeutic applications. Thus, novel formulations ought to not only kill drug resistant strains and cancerous cells but also inhibit their formation. Recently, metallic nanoparticles [for example- silver (Ag) nanoparticles] have been widely investigated for their biomedical applications. The so-called applications necessitate the inclusion of these nanoparticles inside polymeric matrices (for example- dendrimer) leading to chemical functionalization of the metallic nanoparticles. Silver and silver nanoparticles' antibacterial activity has already been well established over years. Dendrimers due to their homogeneous highly branched structure and uniform composition are perfectly suitable for the inclusion of silver nanoparticles [Ag NPs]. Recently, the increasing trend in the development of Ag-dendrimer nanocomposites is attributed to the excellent antibacterial activity of Ag as well as dendrimer's unique properties like variable functional terminal ends and potential antibacterial effect necessarily. This review provides an informative overview regarding the numerous aspects of bactericidal and other biomedical applications of Ag-dendrimer nanocomposites, particularly emphasizing analysis of existing research and prospective worth to the pharmaceutical sector in future. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
- Author
-
Jin, Juan, Xie, Yuhao, Zhang, Jin-Shi, Wang, Jing-Quan, Dai, Shi-Jie, He, Wen-fang, Li, Shou-Ye, Ashby, Charles R., Chen, Zhe-Sheng, and He, Qiang
- Abstract
Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted therapy has replaced radiation therapy and chemotherapy as the main treatment option for RCC due to the lack of significant efficacy with these conventional therapeutic regimens. Sunitinib, a drug used to treat gastrointestinal tumors and renal cell carcinoma, inhibits the tyrosine kinase activity of a number of receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-Kit, rearranged during transfection (RET) and fms-related receptor tyrosine kinase 3 (Flt3). Although sunitinib has been shown to be efficacious in the treatment of patients with advanced RCC, a significant number of patients have primary resistance to sunitinib or acquired drug resistance within the 6–15 months of therapy. Thus, in order to develop more efficacious and long-lasting treatment strategies for patients with advanced RCC, it will be crucial to ascertain how to overcome sunitinib resistance that is produced by various drug resistance mechanisms. In this review, we discuss: 1) molecular mechanisms of sunitinib resistance; 2) strategies to overcome sunitinib resistance and 3) potential predictive biomarkers of sunitinib resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade.
- Author
-
Pang, Kun, Shi, Zhen-Duo, Wei, Liu-Ya, Dong, Yang, Ma, Yu-Yang, Wang, Wei, Wang, Guang-Yue, Cao, Ming-Yang, Dong, Jia-Jun, Chen, Yu-Ang, Zhang, Peng, Hao, Lin, Xu, Hao, Pan, Deng, Chen, Zhe-Sheng, and Han, Cong-Hui
- Abstract
The binding of programmed death-1 (PD-1) on the surface of T cells and PD-1 ligand 1 (PD-L1) on tumor cells can prevent the immune-killing effect of T cells on tumor cells and promote the immune escape of tumor cells. Therefore, immune checkpoint blockade targeting PD-1/PD-L1 is a reliable tumor therapy with remarkable efficacy. However, the main challenges of this therapy are low response rate and acquired resistance, so that the outcomes of this therapy are usually unsatisfactory. This review begins with the description of biological structure of the PD-1/PD-L1 immune checkpoint and its role in a variety of cells. Subsequently, the therapeutic effects of immune checkpoint blockers (PD-1 / PD-L1 inhibitors) in various tumors were introduced and analyzed, and the reasons affecting the function of PD-1/PD-L1 were systematically analyzed. Then, we focused on analyzing, sorting out and introducing the possible underlying mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade including abnormal expression of PD-1/PD-L1 and some factors, immune-related pathways, tumor immune microenvironment, and T cell dysfunction and others. Finally, promising therapeutic strategies to sensitize the resistant patients with PD-1/PD-L1 blockade treatment were described. This review is aimed at providing guidance for the treatment of various tumors, and highlighting the drug resistance mechanisms to offer directions for future tumor treatment and improvement of patient prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. CCT251545 enhances drug delivery and potentiates chemotherapy in multidrug-resistant cancers by Rac1-mediated macropinocytosis.
- Author
-
Qin, Siyuan, Zhang, Zhe, Huang, Zhao, Luo, Yinheng, Weng, Ningna, Li, Bowen, Tang, Yongquan, Zhou, Li, Jiang, Jingwen, Lu, Yi, Shao, Jichun, Xie, Na, Nice, Edouard C., Chen, Zhe-Sheng, Zhang, Jian, and Huang, Canhua
- Abstract
It was well known that P-glycoprotein (P-gp/ABCB1) is a master regulator of multidrug resistance (MDR) in cancers. However, the clinical benefit from blocking this pathway remains inconclusive, which motivates a paradigm shift towards alternative strategies for enhancing drug influx. Using a patient-derived organoid (PDO)-based drug screening platform, we report that the combined use of chemotherapy and CCT251545 (CCT) displays robust synergistic effect against PDOs and reduces proliferation of MDR cancer cells in vitro , and results in regression of xenograft tumors, reductions in metastatic dissemination and recurrence rate in vivo. The synergistic activity mediated by CCT can be mainly attributed to the intense uptake of chemotherapeutic agents into the cells, accompanied by alterations in cell phenotypes defined as a mesenchymal epithelial transformation (MET). Mechanistically, analysis of the transcriptome coupled with validation in cellular and animal models demonstrate that the chemosensitizing effect of CCT is profoundly affected by Rac1-dependent macropinocytosis. Furthermore, CCT binds to NAMPT directly, resulting in elevated NAD levels within MDR cancer cells. This effect promotes the assembly of adherents junction (AJ) components with cytoskeleton, which is required for continuous induction of macropinocytosis and consequent drug internalization. Overall, our results illustrate the potential use of CCT as a combination partner for the commonly used chemotherapeutic drugs in the management of MDR cancers. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance.
- Author
-
Fan, Jingyi, To, Kenneth Kin Wah, Chen, Zhe-Sheng, and Fu, Liwu
- Abstract
Multidrug resistance (MDR) is the phenomenon in which cancer cells simultaneously develop resistance to a broad spectrum of structurally and mechanistically unrelated drugs. MDR severely hinders the effective treatment of cancer and is the major cause of chemotherapy failure. ATP-binding cassette (ABC) transporters are extensively expressed in various body tissues, and actively transport endogenous and exogenous substrates through biological membranes. Overexpression of ABC transporters is frequently observed in MDR cancer cells, which promotes efflux of chemotherapeutic drugs and reduces their intracellular accumulation. Increasing evidence suggests that ABC transporters regulate tumor immune microenvironment (TIME) by transporting various cytokines, thus controlling anti-tumor immunity and sensitivity to anticancer drugs. On the other hand, the expression of various ABC transporters is regulated by cytokines and other immune signaling molecules. Targeted inhibition of ABC transporter expression or function can enhance the efficacy of immune checkpoint inhibitors by promoting anticancer immune microenvironment. This review provides an update on the recent research progress in this field. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer.
- Author
-
Wang, Xuejian, Jiang, Wenyan, Du, Yanmei, Zhu, Dongqi, Zhang, Jian, Fang, Chunyan, Yan, Fang, and Chen, Zhe-Sheng
- Abstract
Dysregulation or aberrant signaling transduction contributes to tumorigenesis. Targeting these abnormal signaling pathways becomes an effective anticancer strategy. However, feedback activation or crosstalk between signaling pathways drives adaptive drug resistance which causes failure of cancer therapy. In this review article, we summarized treatments that cause feedback activation of AKT, ERK, STAT3, EGFR, FGFR, and HER2/3 signaling pathways and the combination therapy to enhance anti-tumor effect or to overcome drug resistance, to explore the underlying mechanisms that define the protein molecules participated or regulated the feedback activation. In addition, we reviewed clinical trials that employ combination treatments to suppress feedback activation and improve therapeutic efficacy of cancer treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.
- Author
-
Huang, Maohua, Lin, Yuning, Wang, Chenran, Deng, Lijuan, Chen, Minfeng, Assaraf, Yehuda G., Chen, Zhe-Sheng, Ye, Wencai, and Zhang, Dongmei
- Abstract
Angiogenesis is a hallmark of cancer and is required for tumor growth and progression. Antiangiogenic therapy has been revolutionarily developing and was approved for the treatment of various types of cancer for nearly two decades, among which bevacizumab and sorafenib continue to be the two most frequently used antiangiogenic drugs. Although antiangiogenic therapy has brought substantial survival benefits to many cancer patients, resistance to antiangiogenic drugs frequently occurs during clinical treatment, leading to poor outcomes and treatment failure. Cumulative evidence has demonstrated that the intricate interplay among tumor cells, bone marrow-derived cells, and local stromal cells critically allows for tumor escape from antiangiogenic therapy. Currently, drug resistance has become the main challenge that hinders the therapeutic efficacies of antiangiogenic therapy. In this review, we describe and summarize the cellular and molecular mechanisms conferring tumor drug resistance to antiangiogenic therapy, which was predominantly associated with redundancy in angiogenic signaling molecules (e.g., VEGFs, GM-CSF, G-CSF, and IL17), alterations in biological processes of tumor cells (e.g., tumor invasiveness and metastasis, stemness, autophagy, metabolic reprogramming, vessel co-option, and vasculogenic mimicry), increased recruitment of bone marrow-derived cells (e.g., myeloid-derived suppressive cells, tumor-associated macrophages, and tumor-associated neutrophils), and changes in the biological functions and features of local stromal cells (e.g., pericytes, cancer-associated fibroblasts, and endothelial cells). We also review potential biomarkers to predict the response to antiangiogenic therapy in cancer patients, which mainly consist of imaging biomarkers, cellular and extracellular proteins, a certain type of bone marrow-derived cells, local stromal cell content (e.g., pericyte coverage) as well as serum or plasma biomarkers (e.g., non-coding RNAs). Finally, we highlight the recent advances in combination strategies with the aim of enhancing the response to antiangiogenic therapy in cancer patients and mouse models. This review introduces a comprehensive understanding of the mechanisms and biomarkers associated with the evasion of antiangiogenic therapy in cancer, providing an outlook for developing more effective approaches to promote the therapeutic efficacy of antiangiogenic therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.
- Author
-
Li, Wen, Zhang, Han, Assaraf, Yehuda G., Zhao, Kun, Xu, Xiaojun, Xie, Jinbing, Yang, Dong-Hua, and Chen, Zhe-Sheng
- Abstract
Multidrug resistance is a key determinant of cancer chemotherapy failure. One of the major causes of multidrug resistance is the enhanced efflux of drugs by membrane ABC transporters. Targeting ABC transporters projects a promising approach to eliminating or suppressing drug resistance in cancer treatment. To reveal the functional mechanisms of ABC transporters in drug resistance, extensive studies have been conducted from identifying drug binding sites to elucidating structural dynamics. In this review article, we examined the recent crystal structures of ABC proteins to depict the functionally important structural elements, such as domains, conserved motifs, and critical amino acids that are involved in ATP-binding and drug efflux. We inspected the drug-binding sites on ABC proteins and the molecular mechanisms of various substrate interactions with the drug binding pocket. While our continuous battle against drug resistance is far from over, new approaches and technologies have emerged to push forward our frontier. Most recent developments in anti-MDR strategies include P-gp inhibitors, RNA-interference, nano-medicines, and delivering combination strategies. With the advent of the ‘Omics’ era – genomics, epigenomics, transcriptomics, proteomics, and metabolomics – these disciplines play an important role in fighting the battle against chemoresistance by further unraveling the molecular mechanisms of drug resistance and shed light on medical therapies that specifically target MDR. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
41. Exploring naturally occurring ivy nanoparticles as an alternative biomaterial.
- Author
-
Huang, Yujian, Wang, Yi-Jun, Wang, Yongzhong, Yi, Sijia, Fan, Zhen, Sun, Leming, Lin, Derrick, Anreddy, Nagaraju, Zhu, Hua, Schmidt, Michael, Chen, Zhe-Sheng, and Zhang, Mingjun
- Subjects
CANCER treatment ,CANCER chemotherapy ,ENGLISH ivy ,NANOMEDICINE ,BIOMATERIALS ,BIOCOMPATIBILITY ,BIODEGRADABLE materials - Abstract
Arabinoglactan protein (AGP)-rich nanoparticles obtained from the sticky exudates of Hedera helix (English ivy), have shown promising potential to be used in nanomedicine owing to their excellent aqueous solubility, low intrinsic viscosity, biocompatibility, and biodegradability. In this study, the feasibilities of utilizing ivy nanoparticles (INPs) as nano-carriers for delivering chemotherapeutic drugs in cancer therapy and as nano-fillers to develop novel scaffolds for tissue engineering in regenerative medicine are evaluated. Via electrostatic and hydrophobic interactions, pH-responsive nanoconjugates are formed between the INPs and the doxorubicin (DOX) with an entrapment ratio of 77.9 ± 3.9%. While the INPs show minimal cytotoxicity, the formed INP-DOX conjugates exhibit substantially stronger cytotoxic activity than free DOX against multiple cancer cell lines, suggesting a synergistic effect is established upon conjugation. The anti-cancer effects of the INP-DOX conjugates are further evaluated via in vivo xenograft assays by subcutaneously implanting DOX resistant cell line, SW620/Ad-300, into nude mice. The tumor volumes in mice treated with the INP-DOX conjugates are significantly less than those of the mice treated with free DOX. In addition, the INPs are further exploited as nano-fillers to develop fibrous scaffolds with collagen, via mimicking the porous matrix where the INPs are embedded under natural condition. Enhanced adhesion of smooth muscle cells (SMCs) and accelerated proliferation of mouse aortic SMCs are observed in this newly constructed scaffold. Overall, the results obtained from the present study suggest great potential of the INPs to be used as biocompatible nanomaterials in nanomedicine. The AGP-rich INP renders a glycoprotein architecture that is amenable for modification according to the functional designs, capable of being developed as versatile nanomaterials for extensive biomedical applications. Statement of Significance Naturally occurring organic nanomaterials have drawn increasing interest for their potential biomedical applications in recent years. In this study, a new type of naturally occurring nanoparticles obtained from the sticky exudates on the adventitious roots of English ivy ( H. helix ), was explored for its potential biomedical application. In particular, the feasibilities of utilizing ivy nanoparticles (INPs) as nano-carriers for delivering chemotherapeutic drugs in cancer therapy and as nano-fillers to develop novel scaffolds for tissue engineering in regenerative medicine were evaluated both in vitro and in vivo . Overall, the results obtained from the present study suggest the great potential of the INPs to be used as biocompatible nanomaterials in nanomedicine. This study may open a totally new frontier for exploring the biomedical application of naturally occurring nanomaterials. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
42. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade.
- Author
-
Kathawala, Rishil J., Gupta, Pranav, Ashby, Charles R., and Chen, Zhe-Sheng
- Abstract
ATP-binding cassette (ABC) transporters represent one of the largest and oldest families of membrane proteins in all extant phyla from prokaryotes to humans, which couple the energy derived from ATP hydrolysis essentially to translocate, among various substrates, toxic compounds across the membrane. The fundamental functions of these multiple transporter proteins include: (1) conserved mechanisms related to nutrition and pathogenesis in bacteria, (2) spore formation in fungi, and (3) signal transduction, protein secretion and antigen presentation in eukaryotes. Moreover, one of the major causes of multidrug resistance (MDR) and chemotherapeutic failure in cancer therapy is believed to be the ABC transporter-mediated active efflux of a multitude of structurally and mechanistically distinct cytotoxic compounds across membranes. It has been postulated that ABC transporter inhibitors known as chemosensitizers may be used in combination with standard chemotherapeutic agents to enhance their therapeutic efficacy. The current paper reviews the advance in the past decade in this important domain of cancer chemoresistance and summarizes the development of new compounds and the re-evaluation of compounds originally designed for other targets as transport inhibitors of ATP-dependent drug efflux pumps. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
43. PD173074, a selective FGFR inhibitor, reverses MRP7 (ABCC10)-mediated MDR.
- Author
-
Anreddy, Nagaraju, Patel, Atish, Sodani, Kamlesh, Kathawala, Rishil J., Chen, Eugenie P., Wurpel, John N.D., and Chen, Zhe-Sheng
- Subjects
FIBROBLAST growth factor receptors ,MULTIDRUG resistance ,ATP-binding cassette transporters ,ANTINEOPLASTIC agents ,TAXANES ,THERAPEUTIC use of alkaloids ,LUNG cancer treatment - Abstract
Abstract: Multidrug resistance protein 7 (MRP7, ABCC10) is a recently identified member of the ATP-binding cassette (ABC) transporter family, which adequately confers resistance to a diverse group of antineoplastic agents, including taxanes, vinca alkaloids and nucleoside analogs among others. Clinical studies indicate an increased MRP7 expression in non-small cell lung carcinomas (NSCLC) compared to a normal healthy lung tissue. Recent studies revealed increased paclitaxel sensitivity in the Mrp7
−/− mouse model compared to their wild-type counterparts. This demonstrates that MRP7 is a key contributor in developing drug resistance. Recently our group reported that PD173074, a specific fibroblast growth factor receptor (FGFR) inhibitor, could significantly reverse P-glycoprotein-mediated MDR. However, whether PD173074 can interact with and inhibit other MRP members is unknown. In the present study, we investigated the ability of PD173074 to reverse MRP7-mediated MDR. We found that PD173074, at non-toxic concentration, could significantly increase the cellular sensitivity to MRP7 substrates. Mechanistic studies indicated that PD173074 (1μmol/L) significantly increased the intracellular accumulation and in-turn decreased the efflux of paclitaxel by inhibiting the transport activity without altering expression levels of the MRP7 protein, thereby representing a promising therapeutic agent in the clinical treatment of chemoresistant cancer patients. [Copyright &y& Elsevier]- Published
- 2014
- Full Text
- View/download PDF
44. Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.
- Author
-
Shukla, Suneet, Chen, Zhe-Sheng, and Ambudkar, Suresh V.
- Subjects
PROTEIN-tyrosine kinases ,ATP-binding cassette transporters ,DRUG resistance ,CELLULAR signal transduction ,CANCER cell proliferation ,APOPTOSIS ,METASTASIS ,NEOVASCULARIZATION inhibitors - Abstract
Abstract: Tyrosine kinases (TKs) are involved in key signaling events/pathways that regulate cancer cell proliferation, apoptosis, angiogenesis and metastasis. Deregulated activity of TKs has been implicated in several types of cancers. In recent years, tyrosine kinase inhibitors (TKIs) have been developed to inhibit specific kinases whose constitutive activity results in specific cancer types. These TKIs have been found to demonstrate effective anticancer activity and some of them have been approved by the Food and Drug Administration for clinical use or are in clinical trials. However, these targeted therapeutic agents are also transported by ATP-binding cassette (ABC) transporters, resulting in altered pharmacokinetics or development of resistance to these drugs in cancer patients. This review covers the recent findings on the interactions of clinically important TKIs with ABC drug transporters. Future research efforts in the development of novel TKIs with specific targets, seeking improved activity, should consider these underlying causes of resistance to TKIs in cancer cells. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
45. Novel nanomedicines to overcome cancer multidrug resistance.
- Author
-
Su, Zhenwei, Dong, Shaowei, Zhao, Shan-Chao, Liu, Kaisheng, Tan, Yao, Jiang, Xingyu, Assaraf, Yehuda G., Qin, Bo, Chen, Zhe-Sheng, and Zou, Chang
- Abstract
Chemotherapy remains a powerful tool to eliminate malignant cells. However, the efficacy of chemotherapy is compromised by the frequent emergence of intrinsic and acquired multidrug resistance (MDR). These chemoresistance modalities are based on a multiplicity of molecular mechanisms of drug resistance, including : 1) Impaired drug uptake into cancer cells; 2) Increased expression of ATP-binding cassette efflux transporters; 3) Loss of function of pro-apoptotic factors; 4) Enhanced DNA repair capacity; 5) Qualitative or quantitative alterations of specific cellular targets; 6) Alterations that allow cancer cells to tolerate adverse or stressful conditions; 7) Increased biotransformation or metabolism of anticancer drugs to less active or completely inactive metabolites; and 8) Intracellular and intercellular drug sequestration in well-defined organelles away from the cellular target. Hence, one of the major aims of cancer research is to develop novel strategies to overcome cancer drug resistance. Over the last decades, nanomedicine, which focuses on targeted delivery of therapeutic drugs into tumor tissues using nano-sized formulations, has emerged as a promising tool for cancer treatment. Therefore, nanomedicine has been introduced as a reliable approach to improve treatment efficacy and minimize detrimental adverse effects as well as overcome cancer drug resistance. With rationally designed strategies including passively targeted delivery, actively targeted delivery, delivery of multidrug combinations, as well as multimodal combination therapy, nanomedicine paves the way towards efficacious cancer treatment and hold great promise in overcoming cancer drug resistance. Herein, we review the recent progress of nanomaterials used in medicine, including liposomal nanoparticles, polymeric nanoparticles, inorganic nanoparticles and hybrid nanoparticles, to surmount cancer multidrug resistance. Finally, the future perspectives of the application of nanomedicine to reverse cancer drug resistance will be addressed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
46. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function.
- Author
-
Gao, Lingyue, Wu, Zhuo-Xun, Assaraf, Yehuda G., Chen, Zhe-Sheng, and Wang, Lihui
- Abstract
The cytotoxic anti-cancer drugs cisplatin, paclitaxel, doxorubicin, 5-fluorouracil (5-FU), as well as targeted drugs including imatinib, erlotinib, and nivolumab, play key roles in clinical cancer treatment. However, the frequent emergence of drug resistance severely comprosises their anti-cancer efficacy. A number of studies indicated that loss of function of tumor suppressor genes (TSGs) is involved in the development of cancer drug resistance, apart from decreased drug influx, increased drug efflux, induction of anti-apoptosis mechanisms, alterations in tumor microenvironment, drug compartmentalization, enhanced DNA repair and drug inactivation. TSGs are involved in the pathogenesis of tumor formation through regulation of DNA damage repair, cell apoptosis, autophagy, proliferation, cell cycle progression, and signal transduction. Our increased understanding of TSGs in the past decades demonstrates that gene mutation is not the only reason that leads to the inactivation of TSGs. Loss of function of TSGs may be based on the ubiquitin-proteasome pathway, epigenetic and transcriptional regualtion, post-translation modifications like phosphorylation as well as cellular translocation of TSGs. As the above processes can constitute"druggable targets", these mechanisms provide novel therapeutic approaches in targeting TSGs. Some small molecule compounds targeting these approaches re-activated TSGs and reversed cancer drug resistance. Along this vein, functional restoration of TSGs is a novel and promising approach to surmount cancer drug resistance. In the current review, we draw a scenario based on the role of loss of function of TSGs in drug resistance, on mechanisms leading to inactivation of TSGs and on pharmacological agents acting on these mechanisms to overcome cancer drug resistance. This review discusses novel therapeutic strategies targeting TSGs and offers possible modalities to conquer cancer drug resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
47. The role of endolysosomal trafficking in anticancer drug resistance.
- Author
-
Hussein, Noor A., Malla, Saloni, Pasternak, Mariah A., Terrero, David, Brown, Noah G., Ashby, Charles R., Assaraf, Yehuda G., Chen, Zhe-Sheng, and Tiwari, Amit K.
- Abstract
Multidrug resistance (MDR) remains a major obstacle towards curative treatment of cancer. Despite considerable progress in delineating the basis of intrinsic and acquired MDR, the underlying molecular mechanisms remain to be elucidated. Emerging evidences suggest that dysregulation in endolysosomal compartments is involved in mediating MDR through multiple mechanisms, such as alterations in endosomes, lysosomes and autophagosomes, that traffic and biodegrade the molecular cargo through macropinocytosis, autophagy and endocytosis. For example, altered lysosomal pH, in combination with transcription factor EB (TFEB)-mediated lysosomal biogenesis, increases the sequestration of hydrophobic anti-cancer drugs that are weak bases, thereby producing an insufficient and off-target accumulation of anti-cancer drugs in MDR cancer cells. Thus, the use of well-tolerated, alkalinizing compounds that selectively block Vacuolar H⁺-ATPase (V-ATPase) may be an important strategy to overcome MDR in cancer cells and increase chemotherapeutic efficacy. Other mechanisms of endolysosomal-mediated drug resistance include increases in the expression of lysosomal proteases and cathepsins that are involved in mediating carcinogenesis and chemoresistance. Therefore, blocking the trafficking and maturation of lysosomal proteases or direct inhibition of cathepsin activity in the cytosol may represent novel therapeutic modalities to overcome MDR. Furthermore, endolysosomal compartments involved in catabolic pathways, such as macropinocytosis and autophagy, are also shown to be involved in the development of MDR. Here, we review the role of endolysosomal trafficking in MDR development and discuss how targeting endolysosomal pathways could emerge as a new therapeutic strategy to overcome chemoresistance in cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. Therapeutic strategies to overcome taxane resistance in cancer.
- Author
-
Das, Tuyelee, Anand, Uttpal, Pandey, Swaroop Kumar, Ashby, Charles R., Assaraf, Yehuda G., Chen, Zhe-Sheng, and Dey, Abhijit
- Abstract
[Display omitted] • Resistance to Taxanesoccurs at molecular and genetic levels. • Taxanes inhibit tubulin depolymerization • Nanocarriers and RNAi techniques decrease the magnitude of resistance to Taxanes. • Secondary metabolites reverse drug resistance by targeting P-gp, β-tubulin and the Akt/NF-κB pathways. One of the primary causes of attenuated or loss of efficacy of cancer chemotherapy is the emergence of multidrug resistance (MDR). Numerous studies have been published regarding potential approaches to reverse resistance to taxanes, including paclitaxel (PTX) and docetaxel, which represent one of the most important classes of anticancer drugs. Since 1984, following the FDA approval of paclitaxel for the treatment of advanced ovarian carcinoma, taxanes have been extensively used as drugs that target tumor microtubules. Taxanes, have been shown to affect an array of oncogenic signaling pathways and have potent cytotoxic efficacy. However, the clinical success of these drugs has been restricted by the emergence of cancer cell resistance, primarily caused by the overexpression of MDR efflux transporters or by microtubule alterations. I n vitro and in vivo studies indicate that the mechanisms underlying the resistance to PTX and docetaxel are primarily due to alterations in α-tubulin and β-tubulin. Moreover, resistance to PTX and docetaxel results from: 1) alterations in microtubule-protein interactions, including microtubule-associated protein 4, stathmin, centriole, cilia, spindle-associated protein, and kinesins; 2) alterations in the expression and activity of multidrug efflux transporters of the ABC superfamily including P-glycoprotein (P-gp/ABCB1); 3) overexpression of anti-apoptotic proteins or inhibition of apoptotic proteins and tumor-suppressor proteins, as well as 4) modulation of signal transduction pathways associated with the activity of several cytokines, chemokines and transcription factors. In this review, we discuss the abovementioned molecular mechanisms and their role in mediating cancer chemoresistance to PTX and docetaxel. We provide a detailed analysis of both in vitro and in vivo experimental data and describe the application of these findings to therapeutic practice. The current review also discusses the efficacy of different pharmacological modulations to achieve reversal of PTX resistance. The therapeutic roles of several novel compounds, as well as herbal formulations, are also discussed. Among them, many structural derivatives had efficacy against the MDR phenotype by either suppressing MDR or increasing the cytotoxic efficacy compared to the parental drugs, or both. Natural products functioning as MDR chemosensitizers offer novel treatment strategies in patients with chemoresistant cancers by attenuating MDR and increasing chemotherapy efficacy. We broadly discuss the roles of inhibitors of P-gp and other efflux pumps, in the reversal of PTX and docetaxel resistance in cancer cells and the significance of using a nanomedicine delivery system in this context. Thus, a better understanding of the molecular mechanisms mediating the reversal of drug resistance, combined with drug efficacy and the application of target-based inhibition or specific drug delivery, could signal a new era in modern medicine that would limit the pathological consequences of MDR in cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance.
- Author
-
Wang, Jing-Quan, Yang, Yuqi, Cai, Chao-Yun, Teng, Qiu-Xu, Cui, Qingbin, Lin, Jun, Assaraf, Yehuda G., and Chen, Zhe-Sheng
- Abstract
ATP-binding cassette (ABC) transporters mediate the ATP-driven translocation of structurally and mechanistically distinct substrates against steep concentration gradients. Among the seven human ABC subfamilies namely ABCA-ABCG, ABCC is the largest subfamily with 13 members. In this respect, 9 of the ABCC members are termed "multidrug resistance proteins" (MRPs1-9) due to their ability to mediate cancer multidrug resistance (MDR) by extruding various chemotherapeutic agents or their metabolites from tumor cells. Furthermore, MRPs are also responsible for the ATP-driven efflux of physiologically important organic anions such as leukotriene C 4 , folic acid, bile acids and cAMP. Thus, MRPs are involved in important regulatory pathways. Blocking the anticancer drug efflux function of MRPs has shown promising results in overcoming cancer MDR. As a result, many novel MRP modulators have been developed in the past decade. In the current review, we summarize the structure, tissue distribution, biological and pharmacological functions as well as clinical insights of MRPs. Furthermore, recent updates in MRP modulators and their therapeutic applications in clinical trials are also discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
50. Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification.
- Author
-
Li, Bowen, Jiang, Jingwen, Assaraf, Yehuda G., Xiao, Hengyi, Chen, Zhe-Sheng, and Huang, Canhua
- Abstract
Despite the development of targeted therapy, drug resistance remains a primary hindrance to curative treatment of various cancers. Among several novel approaches to overcome drug resistance, modulating N
6 -methyladenosine (m6 A) RNA modification was found to be an important strategy in various types of cancer cells. Considered as one of the most common epigenetic RNA modifications, m6 A regulates multiple biological processes including cellular proliferation, metabolism, and metastasis through modulation of RNA splicing, degradation, and translation, leading to anticancer drug resistance. This regulatory network is orchestrated mainly by several m6 A regulators, including "writers", "readers", and "erasers". It is encouraging that several small molecules targeting m6 A regulators have shown great potential in overcoming drug resistance in different cancer cell types, two of which entacapone and meclofenamate, are currently undergoing evaluation. However, the m6 A modification participates in complex biological processes and its functions are context-dependent, which has challenged the clinical application of targeting the m6 A modification in cancer therapy. In this review, we discuss the molecular mechanisms underlying the m6 A modification in regulating anticancer drug resistance through modulation of drug-target interaction and drug-mediated cell death signaling. Alteration of the m6 A modification interferes with drug efficacy through modulation of the expression of multidrug efflux transporters (e.g., ABCG2, ABCC9, ABCC10), drug metabolizing enzymes (e.g., CYP2C8), and drug targets (e.g., p53 R273 H). Furthermore, alterations of the m6 A modification may protect cells from drug-mediated cell death by regulating DNA damage repair (e.g., p53, BRCA1, Pol κ, UBE2B, and ERCC1), downstream adaptive response (e.g., critical regulators of apoptosis, autophagy, pro-survival signaling, and oncogenic bypass signaling), cell stemness, and tumor microenvironment (e.g., ITGA6, ITGB3, and PD-1). We particularly highlight recent advances in therapeutic strategies targeting the m6 A modification with the aim to surmount chemoresistance. The comprehensive understanding of the role of the m6 A modification integrated with combined therapeutic strategies, should facilitate the development of future therapeutic strategies to circumvent or surmount drug resistance, thus enhancing therapeutic efficacy. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.